Akebia Therapeutics Inc. (NASDAQ: AKBA) started the day on September 11, 2020, with a price decrease of -2.69% at $2.53. During the day, the stock rose to $2.67 and sunk to $2.49 before settling in for the price of $2.60 at the close. Taking a more long-term approach, AKBA posted a 52-week range of $2.46-$13.71.
Meanwhile, its Annual Earning per share during the time was 21.70%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 4.50%. This publicly-traded company’s shares outstanding now amounts to $136.91 million, simultaneously with a float of $134.72 million. The organization now has a market capitalization sitting at $367.31 million. At the time of writing, stock’s 50-day Moving Average stood at $10.29, while the 200-day Moving Average is $9.05.
While finding the extent of efficiency of the company that is accounted for 360 employees. It has generated 930,558 per worker during the last fiscal year. Meanwhile, its income per employee was -776,831. The stock had 12.07 Receivables turnover and 0.36 Total Asset turnover. For the Profitability, stocks gross margin was +56.61, operating margin was -85.46 and Pretax Margin of -85.46.
Akebia Therapeutics Inc. (AKBA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Akebia Therapeutics Inc.’s current insider ownership accounts for 0.30%, in contrast to 80.20% institutional ownership. According to the most recent insider trade that took place on Jun 08, this organization’s Director sold 4,567 shares at the rate of 12.05, making the entire transaction reach 55,032 in total value, affecting insider ownership by 24,133. Preceding that transaction, on Jun 08, Company’s Director sold 4,567 for 12.08, making the whole transaction’s value amount to 55,169. This particular insider is now the holder of 38,864 in total.
Akebia Therapeutics Inc. (AKBA) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2020, the organization reported -$1.28 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.5) by -$0.78. This company achieved a net margin of -83.48 while generating a return on equity of -54.27. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
Akebia Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 4.50% and is forecasted to reach -0.67 in the upcoming year.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Trading Performance Indicators
Let’s observe the current performance indicators for Akebia Therapeutics Inc. (AKBA). It’s Quick Ratio in the last reported quarter now stands at 1.80. The Stock has managed to achieve an average true range (ATR) of 0.81. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.08.
In the same vein, AKBA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.01, a figure that is expected to reach -0.17 in the next quarter, and analysts are predicting that it will be -0.67 at the market close of one year from today.
Technical Analysis of Akebia Therapeutics Inc. (AKBA)
If we take a close look at the recent performances of Akebia Therapeutics Inc. (NASDAQ: AKBA), its last 5-days Average volume was 13.24 million that shows progress from its year to date volume of 2.28 million. During the previous 9 days, stock’s Stochastic %D was recorded 1.64% While, its Average True Range was 0.84.
Raw Stochastic average of Akebia Therapeutics Inc. (AKBA) in the period of the previous 100 days is set at 0.62%, which indicates a major fall in contrast to 0.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 539.79% that was higher than 228.50% volatility it exhibited in the past 100-days period.